

To: Keystone First/Keystone First Community HealthChoices (CHC) Providers

Date: May 15, 2025

Subject: Consider prescribing preferred Adalimumab biosimilar products

As you know, Keystone First/Keystone First CHC adheres to the Preferred and Non-preferred status and list of drugs included in the Pennsylvania (PA) Department of Human Services (DHS) statewide preferred drug list (PDL). Humira is on the PA PDL as a preferred option, however there are biosimilar adalimumab products included as preferred PA PDL options. Humira is priced at approximately \$7,000/month versus the biosimilar products priced around \$1,000/month. Given the availability of biosimilar alternatives that provide the same clinical efficacy and safety at a significantly lower cost, we ask that you consider a biosimilar to help support the efficient use of finite healthcare dollars while maintaining quality care.

We are respectfully asking your practice to consider prescribing one of the PA PDL preferred adalimumab biosimilars if any of your Keystone First/Keystone First CHC patients are currently prescribed Humira or you are starting adalimumab therapy. The biosimilars are:

- Adalimumab-fkjp
- Amjevita (adalimumab-atto)
- Hadlima (adalimumab-bwwd)
- Yusimry (adalimumab-aqvh)

Scan the QR codes below to access FDA fact sheets regarding biosimilars to address any concerns you may have regarding the safety and efficacy of these biosimilar agents.

Overview of Biosimilar Products

Biosimilar Regulatory Review and Approval

Interchangeable Biological Products



Thank you for your continued participation in our network and the care you provide to our Members/Participants. If you have any further questions, please feel free to contact Keystone First Pharmacy services at **1-800-588-6767** or Keystone First CHC at **1-866-907-7088**.

Physicians and other health care providers are solely responsible for the treatment decisions for their patients